Matwings' AI Hits Milestone: From Code to Clinic in China's Biotech Boom

SHANGHAI, China – August 20, 2026 – In a move that underscores the growing convergence of artificial intelligence and biotechnology, Shanghai-based Matwings Technology today saw its AI-driven protein engineering platform achieve a critical validation. GenSci148 Injection, an investigational eye therapeutic developed by Changchun GeneScience Pharmaceutical using Matwings' technology, has received clinical trial clearance in China. The green light from regulators for human trials in serious retinal diseases not only offers new hope for patients but also provides tangible proof that Matwings’ iterative AI-driven design process can deliver real-world results, fundamentally altering the economics of drug development.

This milestone is more than just a regulatory checkpoint; it's a powerful signal to the biopharma industry. It validates a novel “closed-loop” approach where AI doesn't just predict outcomes but actively learns and refines designs through real-time lab experiments. For Matwings, which has already parlayed its technological prowess into a new drug development subsidiary, Biowings Therapeutics, this achievement marks a pivotal transition from a promising tech engine to a validated creator of potential therapeutic assets.

The New Blueprint for Drug Design: Beyond Prediction to Iteration

For years, the promise of AI in drug discovery has often been confined to computational benchmarks and one-off predictions. Matwings’ collaboration with GenSci on the GenSci148 program represents a significant operational evolution. Instead of using AI as a single-step mutation prediction tool, the teams implemented a closed-loop system that marries AI-guided design with physical wet-lab testing in a continuous, iterative cycle.

Over the course of the program, 222 protein variants were designed and evaluated across four distinct cycles. The initial rounds focused on a primary goal: improving the molecule’s biological activity. However, as experimental data from the lab flowed back into Matwings' Venus AI platform, the objectives became more complex. The AI was tasked not just with making the drug more potent, but with making it a better product. Subsequent cycles aimed to solve the multi-faceted challenges of drug development, optimizing for thermal stability, protein expression levels, and, crucially, the viscosity of a high-concentration formula—a key factor for manufacturing and patient administration.

This progression from single-objective activity optimization to multi-objective molecular engineering is where the true value lies. It addresses the chasm between a biologically active compound and a commercially viable therapeutic. Some of the AI-identified mutations that proved successful were located far from the protein's conventional target-binding sites, revealing novel engineering pathways that human-led intuition might have missed.

"The real test of AI for science is not whether a model performs well on a benchmark, but whether it can create measurable value through repeated design–experiment cycles in an actual R&D program," said Prof. Liang Hong, Founder and Chief Scientist of Matwings. "GenSci148 marks an important step from demonstrating individual model capabilities toward building a repeatable protein-engineering system."

Engineering a Competitive Edge in a Crowded Market

The clinical trial clearance for GenSci148 places it in one of ophthalmology's most competitive and lucrative markets. The drug is indicated for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO)—conditions that are leading causes of blindness and are currently treated with blockbuster anti-VEGF biologics like aflibercept (Eylea) and faricimab (Vabysmo).

To compete, a new entrant needs a significant clinical advantage. The preclinical data for GenSci148, generated through the AI-driven optimization cycles, suggests such an advantage may be possible. Matwings reported up to a 10-fold improvement in binding affinity to the VEGF-A target and, most notably, sustained inhibitory activity for 84 days in a nonclinical retinal model. This latter finding points toward a potential quarterly dosing schedule, a dramatic improvement over the one-to-two-month intervals required for many current treatments and a major driver of market adoption.

Furthermore, the optimization campaign yielded a 13 cP reduction in viscosity for high-concentration formulations. While seemingly technical, this is a critical bottom-line benefit, potentially simplifying manufacturing, reducing injection-related discomfort, and enabling smaller, more concentrated doses. While the company carefully notes that its preclinical comparisons showing greater inhibition than aflibercept and faricimab are specific to experimental conditions, these early signals are precisely what investors and potential partners look for in a differentiated asset.

From Platform Validation to Pipeline Creation

The GenSci148 program has provided Matwings with its most powerful sales tool: external validation in a real-world therapeutic program. This success has emboldened the company to make a strategic leap from a technology enabler to a value creator. In March 2026, Matwings established Shanghai Biowings Therapeutics, a subsidiary dedicated to developing its own pipeline of internally originated drugs.

This two-pronged strategy is a well-worn path for successful platform companies. Matwings will continue to act as the technology engine, refining its Venus AI stack—which has already advanced two generations beyond the version used for GenSci148—and partnering with other pharma companies. Simultaneously, Biowings Therapeutics will leverage that powerful engine to build its own portfolio of high-value assets, capturing a much larger share of the downstream value. This move transforms the company’s risk profile and upside potential, positioning it as a future integrated biopharma player.

This ambitious strategy is backed by serious capital. Matwings has successfully closed multiple funding rounds, including a recent Series A++ financing in July 2026 that raised over USD 29 million, co-led by state-affiliated funds like SDIC Pioneer and SDIC Innovation, with strong continued support from early investors like Qiming Venture Partners. This influx of capital, particularly from government-linked investors, highlights the strategic importance placed on the company's technology.

"Matwings contributed important molecular engineering and optimization capabilities to the GenSci148 program," affirmed Dr. Lei Jin, CEO of GenSci, highlighting the collaborative success. "Rather than relying on one-time predictions, the teams repeatedly combined AI-guided design with experimental evidence to improve properties relevant to drug development."

A Bellwether for China's 'Innovation 2.0'

Matwings’ success is not an isolated event but a prominent example of China's broader ambition to become a global leader in biopharmaceutical innovation. The country is rapidly moving beyond its past as a generics manufacturer into an era dubbed "Innovation 2.0," characterized by a focus on novel drug discovery and high-quality R&D. Bolstered by regulatory reforms and massive investment, Chinese firms are now significant contributors to the global drug pipeline.

The rise of "AI for Science" (AI4S) is a core component of this national strategy, and companies like Matwings are at the vanguard. They are demonstrating an ability to develop and deploy sophisticated AI systems that can drastically shorten R&D timelines and produce superior molecular candidates. The strong financial backing from both private venture capital and state-sponsored funds indicates a coordinated effort to build a globally competitive AI-driven biotechnology sector. As GenSci148 enters the clinic, it carries not just the hopes of a company, but the ambitions of a nation aiming to redefine the future of medicine.